Volume | 2,023,673 |
|
|||||
News | (1) | ||||||
Day High | 884.61 | Low High |
|||||
Day Low | 876.00 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Eli Lilly and Co | LLY | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
882.55 | 876.00 | 884.61 | 878.45 | 883.33 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
77,711 | 2,023,673 | US$ 879.73 | US$ 1,780,279,029 | - | 434.34 - 885.06 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:58:48 | 1 | US$ 879.64 | USD |
Eli Lilly (LLY) Options Flow Summary
Eli Lilly and Co Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
834.67B | 950.16M | - | 34.12B | 5.24B | 5.52 | 159.28 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Eli Lilly News
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LLY Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 841.50 | 885.06 | 840.39 | 865.99 | 2,906,225 | 38.50 | 4.58% |
1 Month | 771.68 | 885.06 | 766.12 | 828.16 | 2,577,621 | 108.32 | 14.04% |
3 Months | 770.24 | 885.06 | 718.30 | 782.58 | 2,583,992 | 109.76 | 14.25% |
6 Months | 594.50 | 885.06 | 561.65 | 727.68 | 2,923,987 | 285.50 | 48.02% |
1 Year | 444.29 | 885.06 | 434.34 | 633.88 | 2,989,105 | 435.71 | 98.07% |
3 Years | 224.45 | 885.06 | 217.00 | 415.81 | 2,944,998 | 655.55 | 292.07% |
5 Years | 112.13 | 885.06 | 101.36 | 292.35 | 3,289,590 | 767.87 | 684.80% |
Eli Lilly Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. |